Literature DB >> 10823795

Effect of parenteral antibiotic administration on the establishment of colonization with vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract.

C J Donskey1, J A Hanrahan, R A Hutton, L B Rice.   

Abstract

A mouse model of intestinal colonization with vancomycin-resistant enterococci (VRE) was used to study the effect of different beta-lactam antibiotics on establishment of VRE colonization. A clinical VanB VRE isolate, Enterococcus faecium C68 (102 or 104 cfu), was inoculated by gastric gavage in conjunction with subcutaneous administration of antibiotics. The MIC of ceftriaxone and ticarcillin against VRE strain C68 is >10,000 microg/mL, and the MIC of piperacillin is 1250 microg/mL. Ceftriaxone and ticarcillin-clavulanate treatment groups developed persistently high levels of stool VRE compared with both the saline and the piperacillin-tazobactam (Pip-Taz) groups (P<.008). The level of stool VRE in the Pip-Taz group did not differ from that for the saline group. Thus, in this mouse model, beta-lactam antibiotics with minimal anti-enterococcal activity promoted establishment of high-level VRE colonization, but Pip-Taz (a beta-lactam antibiotic with more potent activity against VRE) did not.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10823795     DOI: 10.1086/315428

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

Review 1.  Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci.

Authors:  Stephan Harbarth; Sara Cosgrove; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 2.  Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones.

Authors:  Louis B Rice
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

3.  Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis.

Authors:  Charlie G Buffie; Irene Jarchum; Michele Equinda; Lauren Lipuma; Asia Gobourne; Agnes Viale; Carles Ubeda; Joao Xavier; Eric G Pamer
Journal:  Infect Immun       Date:  2011-10-17       Impact factor: 3.441

4.  Antibiotic-induced enterococcal expansion in the mouse intestine occurs throughout the small bowel and correlates poorly with suppression of competing flora.

Authors:  Viera Lakticová; Rebecca Hutton-Thomas; Matthew Meyer; Evren Gurkan; Louis B Rice
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

5.  The complex dynamics of antimicrobial activity in the human gastrointestinal tract.

Authors:  Louis B Rice
Journal:  Trans Am Clin Climatol Assoc       Date:  2013

Review 6.  Antibiotics and gastrointestinal colonization by vancomycin-resistant enterococci.

Authors:  L B Rice
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

7.  Ampicillin in Combination with Ceftaroline, Cefepime, or Ceftriaxone Demonstrates Equivalent Activities in a High-Inoculum Enterococcus faecalis Infection Model.

Authors:  Megan K Luther; Louis B Rice; Kerry L LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 8.  Pathogenicity of Enterococci.

Authors:  Elizabeth Fiore; Daria Van Tyne; Michael S Gilmore
Journal:  Microbiol Spectr       Date:  2019-07

9.  Effect of Surotomycin, a Novel Cyclic Lipopeptide Antibiotic, on Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice.

Authors:  Abhishek Deshpande; Kelly Hurless; Jennifer L Cadnum; Laurent Chesnel; Lihong Gao; Luisa Chan; Sirisha Kundrapu; Alexander Polinkovsky; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

10.  Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus.

Authors:  Yehuda Carmeli; George M Eliopoulos; Matthew H Samore
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.